NCT07328607Recruiting
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
Open Versus Laparoscopic Pancreaticoduodenectomy: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 27 Dec 2025
- Start date
- 17 Jan 2026
- Primary completion date
- 15 Jan 2028
- Lead sponsor
- Minia University
- NCT number
- NCT07328607
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 17 Jan 2026 to the primary completion date, 15 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Emergency surgery.
- Previous pancreatic surgery.
- Concurrent major abdominal procedures .
- Severe cardiopulmonary comorbidities precluding major surgery.
Other illness
- Metastatic disease identified preoperatively.
- Locally advanced unresectable disease.
- Active infection or sepsis at time of surgery.
Other
- ASA classification IV or higher.
- Pregnancy.
- Procedures requiring Total Pancreatectomy, Distal Pancreatectomy, or Enucleation .
Who the study is looking for
- Age ≥18 years.
- Histologically confirmed or clinically suspected lesions of: Pancreatic head adenocarcinoma, Ampullary carcinoma, Distal cholangiocarcinoma, Duodenal adenocarcinoma, Pancreatic neuroendocrine tumors, or Intraductal Papillary Mucinous Neoplasm(IPMN) .
- Resectable disease based on preoperative imaging.
- Eastern Cooperative Oncology Group(ECOG) performance status 0-2.
- American Society of Anesthesiologists(ASA )classification I-III.
- Patients able to provide informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liver and GIT hospital , Minia University Coordinator of this site? Confirm its status | Minya | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.